Recently, the DDGP chemotherapy program independently researched and founded by the team of professor Zhang Mingzhi of the Oncology Department of the First Affiliated Hospital of Zhengzhou University was adopted by the 2020 American National Comprehensive Cancer Network (NCCN) guidelines and became the first-line chemotherapy recommended by the NCCN guidelines for the treatment of NK / T cell lymphoma. The NCCN guideline is the most authoritative international cancer diagnosis and treatment guideline. The DDGP is the first tumor treatment program written in the NCCN guideline in Henan Province.
It has been proved that,compared with the traditional Japanese SMILE program,the DDGP program for the treatment of NK/T cell lymphoma founded by professor Zhang’s team has no progression survival rate in 3 years (56.6% vs 41.8%,P=0.004), 5- year total survival rate (74.3% vs 51.7%,P=0.02),total response rate (90.0% vs 60.0%,P=0.002) were significantly higher than in the SMILE group,while the incidence of adverse reactions and treatment-related mortality were lower than in the SMILE group. The related findings were published successively in Nature Communications,Clinical Cancer Research,Leukemia and other internationally renowned journals,and at the 61stAnnual meeting of the international top blood oncology (ASH) in2019，professor Zhang gave an oral presentation, and it was named the “Top 10 Lymphoma Research Progress of 2019” by the oncology Branch of the Chinese Medical Association.
